Russell Investments Group’s iRadimed IRMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $9.58M | Sell |
99,498
-9,687
| -9% | -$969K | 0.01% | 969 |
|
|
2025
Q4 | $10.6M | Buy |
109,185
+5,591
| +5% | +$480K | 0.01% | 878 |
|
|
2025
Q3 | $7.37M | Sell |
103,594
-44,971
| -30% | -$3M | 0.01% | 1076 |
|
|
2025
Q2 | $8.88M | Sell |
148,565
-4,739
| -3% | -$260K | 0.01% | 897 |
|
|
2025
Q1 | $8.05M | Sell |
153,304
-6,828
| -4% | -$384K | 0.01% | 919 |
|
|
2024
Q4 | $8.81M | Sell |
160,132
-27,366
| -15% | -$1.44M | 0.01% | 873 |
|
|
2024
Q3 | $9.43M | Buy |
187,498
+27,079
| +17% | +$1.25M | 0.01% | 861 |
|
|
2024
Q2 | $7.05M | Sell |
160,419
-6,465
| -4% | -$275K | 0.01% | 981 |
|
|
2024
Q1 | $7.34M | Sell |
166,884
-44,404
| -21% | -$1.96M | 0.01% | 981 |
|
|
2023
Q4 | $10M | Buy |
211,288
+4,715
| +2% | +$198K | 0.02% | 788 |
|
|
2023
Q3 | $9.17M | Sell |
206,573
-11,975
| -5% | -$556K | 0.02% | 788 |
|
|
2023
Q2 | $10.4M | Buy |
218,548
+5,892
| +3% | +$266K | 0.02% | 757 |
|
|
2023
Q1 | $8.37M | Buy |
212,656
+10,163
| +5% | +$369K | 0.02% | 854 |
|
|
2022
Q4 | $5.73M | Sell |
202,493
-55,740
| -22% | -$1.59M | 0.01% | 1024 |
|
|
2022
Q3 | $7.76M | Buy |
258,233
+11,969
| +5% | +$417K | 0.02% | 844 |
|
|
2022
Q2 | $8.36M | Buy |
246,264
+27,059
| +12% | +$970K | 0.02% | 854 |
|
|
2022
Q1 | $9.83M | Sell |
219,205
-9,083
| -4% | -$420K | 0.02% | 836 |
|
|
2021
Q4 | $10.5M | Buy |
228,288
+42,599
| +23% | +$1.72M | 0.02% | 872 |
|
|
2021
Q3 | $6.24M | Sell |
185,689
-41,062
| -18% | -$1.4M | 0.01% | 1121 |
|
|
2021
Q2 | $6.67M | Sell |
226,751
-103,978
| -31% | -$2.87M | 0.01% | 1166 |
|
|
2021
Q1 | $8.52M | Sell |
330,729
-90,158
| -21% | -$2.15M | 0.02% | 1043 |
|
|
2020
Q4 | $9.6M | Buy |
420,887
+39,369
| +10% | +$910K | 0.02% | 878 |
|
|
2020
Q3 | $8.15M | Buy |
381,518
+47,941
| +14% | +$1.08M | 0.02% | 871 |
|
|
2020
Q2 | $7.74M | Buy |
333,577
+25,070
| +8% | +$538K | 0.02% | 859 |
|
|
2020
Q1 | $6.58M | Buy |
308,507
+34,353
| +13% | +$818K | 0.02% | 823 |
|
|
2019
Q4 | $6.41M | Buy |
274,154
+202,835
| +284% | +$4.74M | 0.01% | 1075 |
|
|
2019
Q3 | $1.5M | Buy |
+71,319
| New | +$1.46M | ﹤0.01% | 1830 |
|
|
2019
Q2 | – | Sell |
-62,913
| Closed | -$1.77M | – | 2912 |
|
|
2019
Q1 | $1.77M | Sell |
62,913
-13,899
| -18% | -$364K | ﹤0.01% | 1786 |
|
|
2018
Q4 | $1.88M | Buy |
76,812
+20,073
| +35% | +$539K | ﹤0.01% | 1640 |
|
|
2018
Q3 | $2.1M | Sell |
56,739
-31,484
| -36% | -$850K | ﹤0.01% | 1730 |
|
|
2018
Q2 | $1.83M | Buy |
88,223
+29,105
| +49% | +$514K | ﹤0.01% | 1806 |
|
|
2018
Q1 | $834K | Buy |
59,118
+24,097
| +69% | +$343K | ﹤0.01% | 2280 |
|
|
2017
Q4 | $548K | Buy |
+35,021
| New | +$445K | ﹤0.01% | 2399 |
|
|
2017
Q1 | – | Sell |
-8,565
| Closed | -$96K | – | 3030 |
|
|
2016
Q4 | $96K | Buy |
+8,565
| New | +$92.2K | ﹤0.01% | 2886 |
|
Other funds holding IRMD
CCM
VCM
NTCM
Russell Investments Group's IRMD Position: Q1 2026 in Review
Russell Investments Group reduced its iRadimed (IRMD) stake by 8.9% in Q1 2026, selling an estimated $969K and leaving 99,498 shares worth $9.58M. The position accounts for 0.01% of the portfolio, ranked #969.
Russell Investments Group first reported a position in IRMD in Q4 2016 and has held it in 34 quarters since. The position peaked at $10.6M in Q4 2025. 228 funds tracked by Wall St. Rank hold IRMD as of Q1 2026.
- Russell Investments Group held 99,498 shares of iRadimed worth $9.58M as of Q1 2026.
- Russell Investments Group sold 9,687 iRadimed shares in Q1 2026, an estimated $969K.
- iRadimed made up 0.01% of Russell Investments Group's portfolio in Q1 2026, its #969 holding.
- Russell Investments Group first reported a position in iRadimed in Q4 2016 and has held it in 34 quarters since.
- Russell Investments Group's iRadimed position peaked at $10.6M in Q4 2025.
- 228 funds tracked by Wall St. Rank held iRadimed as of Q1 2026.
Based on Russell Investments Group's 13F filing for Q1 2026, filed 8 May 2026.